Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Amgen IncAMGN123.675.6029.2219.5749.27%3.32%61.95$319.14$107.7140,964$322.41

Detail of Amgen Inc

 
CEO
Mr. Robert A. Bradway
Employees
26700
Industry
Drug Manufacturers - General
Sector
Healthcare
Market cap
$173B

Company details

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OTH
OI
OIE
PI
TAX
NI
Revenue (Rev)
$30.93B
Cost of goods (CoG)
-$11.35B
Gross profit (GP)
$19.58B
Operating expense (OE)
-$13.39B
Research and development (R&D)
-$5.40B
General and administrative (G&A)
-$7.22B
Other (OTH)
-$765.00M
Operating income (OI)
$6.19B
Other income expense (OIE)
-$545.00M
Pretax income (PI)
$3.52B
Tax (TAX)
-$395.00M
Net income (NI)
$3.13B
Amgen Inc
AMGN • XNGS • US
$322.41
+51.16 (18.86%)
Stock vs Industry average
  • Industry average

Dividend yield
2.75%
Trailing annual dividend rate
$8.76
Payout ratio
151.03%
EPS
$2.61
Margin profit
10.12%
52 week low
$255.699997
52 week high
$338.845001
50-day simple moving average
$319.42
200-day simple moving average
$319.14
Percent held by insiders
0.25%
Percent held by institutions
81.10%
Dividend yield
2.61%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
AMGN +13.68%
eps change
AMGN -46.12%